Addition Therapeutics
Addition Therapeutics develops genetic medicines using its proprietary PRINT technology.
$100M Series A ·
Led by Abingworth · Source: Pulse 2.0
Funding history ↓Signals
About Addition Therapeutics
This technology combines RNA therapeutics and gene therapies to deliver functional cures for patients with severe lifelong diseases. The company focuses on rare patient populations and aims to address larger related patient populations.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $100M | Pulse 2.0 |
Timeline
- Website created
Founders and team
KC
Kathleen Collins FounderRP
Ronald Park CEOFG
Francine Gregoire Chief Scientific Officer
Investors
AAbingworthlead investor
BBEVC
BBill & Melinda Gates Foundation
OOUP (Osage University Partners)
PPivotal Life Scienceslead investor
SSR Onelead investor
Companies like Addition Therapeutics
TTune Therapeutics$175M Series B+ · Jan 2025
SSplice Bio$140M Series B+ · Jun 2025
AAlia Therapeutics$5M Seed · Apr 2023AActio Biosciences$66M Series B+ · Jun 2025
RReCode TherapeuticsSeries B+ · Oct 2023MMirador Therapeutics$250M Series B+ · Jan 2026
Other companies backed by Abingworth
NNouscom$135.04M Series B+ · Oct 2026
RR1 Therapeutics$80.5M Series A · Sep 2026
AAdvanCell$315M Series B+ · Jul 2026
GGlycomine$115M Series B+ · May 2025
MMyricx Bio$120M Series A · Jul 2024
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/addition-therapeutics (get a free API key).